Regulation & Legality

Quick Answer Peptide regulation varies dramatically by country, compound, and intended use – from FDA-approved prescription drugs in the US […]

Quick Answer The peptide market in 2026 is defined by three forces pulling in different directions: a branded therapeutics sector

Quick Answer “Chinese peptides” is a cultural term for grey market peptides manufactured in China and sold through unregulated channels

Quick Answer The TGA has imposed over AUD 10 million in penalties for peptide-related offences since 2018, scheduled BPC-157 as

Quick Answer The MHRA’s Criminal Enforcement Unit has seized over 25 million doses of illegally traded medicines valued at more

Quick Answer Most research peptides became prescription medicines in New Zealand in December 2025 after Medsafe introduced ten group scheduling

Quick Answer Germany has the most complex peptide regulatory landscape in the EU, governed by two separate laws: the Arzneimittelgesetz

Quick Answer In the European Union, peptides intended for human therapeutic use are classified as medicinal products under Directive 2001/83/EC

Quick Answer Canada regulates injectable peptides as prescription drugs under the Food and Drugs Act – any product sold without

Quick Answer Large-scale compounded semaglutide and tirzepatide were legal only while those drugs were in shortage, and with both shortages